The sponsorship was transferred to IDEA Innovative Drug European Associates (Ireland) Limited, Ireland, in September 2019.
On 12 October 2017, orphan designation (EU/3/17/1938) was granted by the European Commission to ProQR Therapeutics VII BV, the Netherlands, for antisense oligonucleotide targeting exon 73 in the COL7A1 gene (also known as QR-313) for the treatment of epidermolysis bullosa.
antisense oligonucleotide targeting exon 73 in the COL7A1 gene
|Disease / condition||
Treatment of epidermolysis bullosa
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.